Latest News

image

Programme for MPS VI meeting announced

The line up for the expert and patient meeting on Maroteaux Lamy Disease (MPS VI) has been announced and is now open for bookings. This is the first time a meeting dedicated to MPS VI has been held by the Society for

Read More
image

Lysogene launches a prospective, observational study of MPS IIIA

Lysogene has launched a prospective, observational study of patients, who are aged nine years old or younger, with mucopolysaccharidosis IIIA (MPS IIIA) to better understand their health problems and how to measure these problems over time. This is an observational

Read More
image

Thank you!

Thank you to everyone who helped us to mark MPS Awareness Day on 15th May 2016! Whether you Wore It Blue, Took to the Skies, held a party, bake sale or raffle, you all did a great job of raising

Read More
image

Approval for Galafold™ in patients with Fabry announced

Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, today announced that the European Commission has granted full approval for the oral small molecule pharmacological chaperone Galafold™ (migalastat) as a first line therapy for long-term treatment

Read More

MPS in numbers

896

individual and families
supported in 2015

25

rare disease supported

3,364,628

£ given research projects
between 1984-2010